Graydon Hansen Net Worth

The estimated Net Worth of Graydon C. Hansen is at least $6.28 Milione dollars as of 11 May 2021. Mr. Hansen owns over 16,606 units of Staar Surgical Co stock worth over $268,153 and over the last 5 years he sold STAA stock worth over $6,015,480. In addition, he makes $0 as Chief Manufacturing Officer and Senior Vice President e Global Operations at Staar Surgical Co.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hansen STAA stock SEC Form 4 insiders trading

Graydon has made over 5 trades of the Staar Surgical Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 16,606 units of STAA stock worth $1,848,580 on 11 May 2021.

The largest trade he's ever made was selling 33,790 units of Staar Surgical Co stock on 1 March 2021 worth over $3,491,521. On average, Graydon trades about 15,096 units every 90 days since 2019. As of 11 May 2021 he still owns at least 8,847 units of Staar Surgical Co stock.

You can see the complete history of Mr. Hansen stock trades at the bottom of the page.

Graydon Hansen biography

Graydon C. Hansen serves as Chief Manufacturing Officer and Senior Vice President, Global Operations of the Company. Mr. Hansen joined STAAR in January 2016 as Vice President of Operations. In October 2017, he assumed the role of Senior Vice President Global Operations, and then in August 2019 assumed the role of Chief Manufacturing Officer and Senior Vice President, Global Operations. From 2009 through 2014, he served as Site Director and General Manager of Abbott Medical Optics medical device manufacturing site in Hangzhou, China, and from 2014 through 2016 as Program Director, Global Operations Strategy at Abbott Medical Optics division headquarters in Orange County, California. He holds a Bachelor of Science degree in Electrical Engineering and Computer Sciences from the University of California, Berkeley, as well as a Master of Business Administration degree from Auburn University.

How old is Graydon Hansen?

Graydon Hansen is 62, he's been the Chief Manufacturing Officer and Senior Vice President e Global Operations of Staar Surgical Co since 2019. There are 5 older and 16 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.

What's Graydon Hansen's mailing address?

Graydon's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.

Insiders trading at Staar Surgical Co

Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal... e Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.

What does Staar Surgical Co do?

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Complete history of Mr. Hansen stock trades at Staar Surgical Co

Staar Surgical Co executives and stock owners

Staar Surgical Co executives and other stock owners filed with the SEC include:

• Caren Mason,
  President, Chief Executive Officer, Director
• Scott Barnes,
  Chief Medical Officer
• Keith Holliday,
  Chief Technology Officer
• Caren L. Mason,
  CEO, Pres & Director
• Hans-Martin Blickensdoerfer,
  Senior Vice President - Commercial Operations, Direct Markets Europe and China
• Samuel Gesten,
  Chief Legal Officer, Corporate Secretary
• Dr. Scott D. Barnes M.D.,
  Chief Medical Officer
• James Francese,
  Senior Vice President - Commercial Operations, North America and APAC
• Hans-Martin Blickensdoerfer,
  Sr. VP of Commercial Operations and Director of Markets - Europe & China
• Dr. Keith Holliday,
  Chief Technology Officer
• Patrick F. Williams,
  Chief Financial Officer
• Louis Silverman,
  Independent Chairman of the Board
• Stephen Farrell,
  Independent Director
• John Moore,
  Independent Director
• Patrick Williams,
  Chief Financial Officer
• Gilbert Kliman,
  Director
• Thomas Frinzi,
  Director
• Brian Moore,
  IR Contact Officer
• Jon Hayashida,
  Vice President - Global Clinical and Medical Affairs
• Graydon Hansen,
  Chief Manufacturing Officer and Senior Vice President, Global Operations
• Philippe Subrin,
  VP of Collamer Lens Manufacturing & GM of Nidau Operations
• Joanne Egamino Ph.D.,
  Global Head of Clinical Operations
• James Francese,
  Sr. VP of Commercial Operations - North America & APAC
• William Goodmen,
  VP of Global HR
• Samuel J. Gesten,
  Chief Legal Officer & Corp. Sec.
• Lou Silverman,
  Director
• Stephen P Brown,
  Vice President & Chief Financi
• Richard A Meier,
  Director
• Partners, L.P.Broadwood Cap...,
  
• Partners, L.P.Bradsher Neal...,
  
• William P Wall,
  Director
• David Bailey,
  President and CEO
• Robert Studholme,
  Senior VP, Operations
• Wei Jiang,
  
• Arthur C Butcher,
  
• Nathaniel Sisitsky,
  General Counsel
• Nicholas T Curtis,
  Sr. VP Sales and Marketing
• Paul Hambrick,
  Vice President, Operations
• Robert Kenneth Lally,
  Vice President, QA/RA
• David L Schlotterbeck,
  Director
• James I Farnworth,
  VP Reg Affairs & Quality
• Gunther Roepstorff,
  President - Domilens GmbH
• John R Gilbert,
  Director
• Thomas R Paul,
  Vice President - R & D
• John Bily,
  Chief Financial Officer
• Volker D Anhaeusser,
  Director
• John S Santos,
  Sr. VP Planning & Corp Dev
• Jack Steven Roush,
  
• Charles P Slacik,
  Director
• Robin Hughes,
  Vice President, Marketing
• Mark B Logan,
  Director
• Barry G Caldwell,
  Director
• Don M Bailey,
  Director
• Kathryn Tunstall,
  Director
• Philippe Subrin,
  VP Switzerland OP
• Charles S Kaufman,
  V.P. , General Counsel
• Donald J Todd,
  President, Asia/Pacific
• Donald L Fagen,
  V.P. Sales for N. America
• David R Morrison,
  Director
• Craig Felberg,
  VP, R&D and Clinical Affairs
• William Walter Goodmen,
  Global VP, Human Resources
• Donald Duffy,
  Director
• Isamu Kamijo,
  President, STAAR Japan Inc.
• K Peony Yu,
  Director
• Aimee S Weisner,
  
• Magda Michna,
  Chief Clinical, Regulatory,
• Warren Foust,
  Chief Operating Officer
• Elizabeth Yeu Lin,
  
• Lilian Yansheng Zhou,